[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619423":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":18,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":18,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crohn's Disease Exclusion Diet + Anti-TNF-α biologics","EXPERIMENTAL","Participants in this group will receive anti-TNF-α biologics (infliximab 5mg\u002Fkg IV at weeks 0, 2, 6, and 14, or adalimumab subcutaneous injection at standard doses) combined with the Crohn's Disease Exclusion Diet (CDED). The CDED protocol includes detailed dietary guidance specifying allowed foods (rice, certain vegetables and fruits, fish, poultry, olive oil) and prohibited items (ultra-processed foods, nuts, legumes, butter). Patients will maintain daily food diaries and receive frequent supervision and guidance from researchers to ensure dietary compliance.",[13],"Other: Crohn's Disease Exclusion Diet",{"label":15,"type":16,"description":17,"interventionNames":18},"Anti-TNF-α biologics only","NO_INTERVENTION","Participants in this group will receive anti-TNF-α biologics alone (infliximab 5mg\u002Fkg IV at weeks 0, 2, 6, and 14, or adalimumab subcutaneous injection at standard doses) without any dietary intervention. This group serves as the control to evaluate the additional benefit of CDED when combined with standard biologic therapy. No specific dietary restrictions or guidance will be provided to this group.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Crohn's Disease Exclusion Diet","Participants will receive anti-TNF-α biologics (infliximab 5mg\u002Fkg IV at weeks 0, 2, 6, and 14, or adalimumab subcutaneous injection at standard doses) combined with the Crohn's Disease Exclusion Diet (CDED). The CDED protocol includes detailed dietary guidance specifying allowed foods (rice, certain vegetables and fruits, fish, poultry, olive oil) and prohibited items (ultra-processed foods, nuts, legumes, butter). Patients will maintain daily food diaries and receive frequent supervision and guidance from researchers to ensure dietary compliance throughout the 14-week study period. This combined intervention aims to evaluate whether CDED can synergistically enhance the efficacy of standard biologic therapy in achieving mucosal healing in Crohn's disease patients.",[9],[25],{"facility":26,"status":18,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Sixth afflicated of Sun-yat sen university","Guangzhou","Guangdong","510655","China","CN",{"type":33,"coordinates":34},"Point",[35,36],113.25,23.11667,{"lat":36,"lon":35},[39],{"name":26,"role":40,"phone":41,"phoneExt":18,"email":42},"CONTACT","020-38379764","zslylb@mail.sysu.edu.cn",{"type":44,"investigatorFullName":45,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Wei Wang","100619423","efficacy-and-safety-of-cded-with-anti-tnf--biologics-in-crohns-disease-100619423",false,"NCT07344428","Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease","Therapeutic Effect of Exclusion Diet Combined With Anti-TNF-α Biologics in Adult Patients With Crohn's Disease in China: A Single-center, Prospective, Randomized, Controlled Trial","CDED","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of Crohn's disease confirmed by endoscopy and histopathology, with active disease (CDAI ≥150).\n* Indicated for anti-TNF-α biologic therapy (infliximab or adalimumab) and naïve to these agents.\n* Willing and able to provide written informed consent.\n* Able to understand and comply with study requirements, including dietary intervention and scheduled follow-up.\n\nExclusion Criteria:\n\n* Presence of severe complications requiring surgical intervention (e.g., intestinal obstruction, intra-abdominal abscess, intestinal fistula).\n* Severe cardiac, hepatic, or renal insufficiency (e.g., Child-Pugh class C, or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Active tuberculosis, active hepatitis B, HIV infection, or other severe opportunistic infections.\n* Current or history of malignancy, except non-melanoma skin cancer.\n* Pregnant or breastfeeding, or planning pregnancy during the study period.\n* Recent use (within 3 months) of other immunosuppressants (e.g., azathioprine, methotrexate) or high-dose corticosteroids (e.g., prednisone \\>20 mg\u002Fday).\n* Severe food allergies, celiac disease, severe malnutrition (BMI \\\u003C18.5 kg\u002Fm²), or inability to adhere to CDED.\n* Concurrent participation in another clinical trial, or any condition that makes the patient unsuitable in the investigator's opinion.","ALL","18 Years",{"count":57,"type":58},185,"ESTIMATED","INTERVENTIONAL",[61],"NA","Crohn's disease (CD) is a chronic inflammatory bowel disease with high recurrence and surgical rates. Mucosal healing is a key therapeutic goal, yet current anti-TNF-α biologics achieve only about 30% mucosal healing. Dietary intervention, particularly the Crohn's Disease Exclusion Diet (CDED), shows promise in CD management. Preliminary data suggest that combining CDED with anti-TNF-α biologics may significantly improve mucosal healing rates (42.9% vs 25%). This single-center, prospective, randomized, controlled trial will enroll 185 adult CD patients with active disease (SES-CD ≥3), randomly assigned 1:1 to receive either anti-TNF-α biologics plus CDED or anti-TNF-α biologics alone. The primary endpoint is mucosal healing rate at week 14 (SES-CD=0). Secondary endpoints include clinical remission, endoscopic response, transmural healing, and adverse events. This study aims to provide high-quality evidence for the efficacy and safety of this combined approach in Chinese CD patients.",[64],"Crohn Disease",[21,66],"mucosal healing","NOT_YET_RECRUITING","2026-07-08",{"date":70,"type":71},"2026-07-10","ACTUAL",{"date":73,"type":58},"2026-08-01",{"date":75,"type":58},"2028-05-01",{"name":5,"class":6},1]